SlideShare a Scribd company logo
1 of 49
L’ (in) appropriatezza  dell’endoscopia superiore C.  Hassan
ENDOSCOPY PATIENT NON-GI REFERRING PHYSICIAN
Medico richiedente N % MMG 3794 60,5 Medico Osped.  2268 36,2 Specialista est.  124 2,0 n.i. 84 1,3 TOTALE 6270 100
ENDOSCOPY PATIENT NON-GI REFERRING PHYSICIAN GI GUIDELINES
[object Object],[object Object],[object Object]
“… on how endoscopy should be performed,  by whom, and for what purposes”
 
 
[object Object],[object Object]
RESULTS ,[object Object],8,252 pts. Main indication N° patients (%) Dyspepsia without reflux § 2,489 ( 30 ) Dyspepsia with reflux § 1,075 ( 13 ) Refl ux § 1,175 ( 14 ) Atypical manifestations of reflux § 129 (2) Alarm features 2,236 ( 27 ) Portal hypertension assessment 324 (4) Suspicion at RX 73 (1) Operative endoscopy 121 (1) Follow up benign/precancerous/malignant 381 (5) Duodenal biopsy 166 (2) EGD for other medical/surgical conditions 74 (1) Cancer of unknown origin 10 (0.1)
 
 
13 856 PATIENTS 22% NOT INDICATED Author N° patients Inappropriateness Rate % Hassan  et al. 6270 23 Rossi  et al. 1777 16 Chan  et al. 1076 12 Froelhich  et al. 1681 39 Bersani  et al. 2000 10 Al Romaih  et al. 80 28 Kaliszan  et al. 522 30 Gonvers  et al. 450 43
Età - Giudizio richiesta A P < 0.05
Tip. Esame   –   Giudizio rich. P < 0.05
INAPPROPR. Vs MEDICO P < 0.05
ASMaD Onlus www.santeugenioroma.org
[object Object],[object Object],[object Object]
RESULTS ,[object Object],Relevant findings Whole population (8,252 pts.) N° (%) Oesophagus Peptic oesophagitis 1,118 (13.5) Varices 427 ( 5.2) Barrett oesophagus * 150 (1.8) Micotic oesophagitis 67 ( 0.8) Cancer § 76 (1) Foreign body  28 ( 0.3) Peptic stricture 15 ( 0.2) Mallory-Weiss 16 (0.2) Anastomotic stricture 7  ( 0.1) Caustic lesion 7 ( 0.1) Caustic stricture 4 ( 0.05)
RESULTS ,[object Object],Relevant findings Whole population (8,252 pts.) N° (%) Stomach Erosive gastritis 989 (12.0) Hypertensive gastropathy 307 ( 3.7) Polyp 228 ( 2.8) Peptic ulcer  219 (2.7) Cancer § 111 (1.3) Stomitis 81 ( 1.0) Fundus varices 39 ( 0.5) Anastomotic ulcer  28 ( 0.3) Gastric antral vascular ectasia 24 ( 0.3) Angiodysplasia 20 ( 0.2) Lymphoma § 17 ( 0.2) Foreig body 20 ( 0.2) Anastomotic stricture 7 ( 0.1) Menetrier syndrome 2 ( 0.002)
RESULTS ,[object Object],Relevant findings Whole population (8,252 pts.) N° (%) Duodenum Erosive duodenitis 340 (4.1) Duodenal ulcer 300 (3.6) Signs of malabsorption 84 (1) Cancer § 15 (0.2) Ampulloma  4 (0.05)
RESULTS New malignancy 1.6% (132 pts.) -Cancer 128 pts. -Lymphoma    4 pts.
RESULTS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
13 856 PATIENTS 45% RELEVANT FINDINGS Author N° patients Relevant findings % Hassan  et al. 6270 49 Rossi  et al. 1777 45 Chan  et al. 1076 38 Froelhich  et al. 1681 54 Bersani  et al. 2000 51 Al Romaih  et al. 80 32 Kaliszan  et al. 522 46 Gonvers  et al. 450 46
51% 32% NOT INDICATED INDICATED 13 856 PATIENTS 78% 22% RELEVANT FINDINGS RELEVANT FINDINGS
Appropriateness of the indication for upper endoscopy:  a meta-analysis Di Giulio E, Hassan C, Zullo A, et al. , DLD 2009 ASGE guidelines Sens. Spec. PPV NPV Relevant finding 85% 28% 49% 70%
DIAGNOSI RILEVANTI vs APPROPRIATEZZA Endoscopic finding OR [99% CI] Clinically relevant Erosive esophagitis  1.28 [0.35-1.63]  Erosive gastritis  1.79 [1.35-2.36] * Esophageal varices  5.65 [2.96-10.8] * Duodenal ulcer  3.38 [1.98-5.76] * Barrett’s esophagus  3.58 [1.59-8.08] * Gastric ulcer  3.41 [1.51-7.71] * Not clinically relevant Nonerosive gastritis  0.78 [0.66-0.9] * Normal  0.40 [0.33-0.49] * Hiatal hernia  0.63 [0.51-0.77] *
2.4% 0.13% NOT INDICATED INDICATED 13 856 PATIENTS 78% 22% CANCER CANCER
b) Appropriateness of the indication for upper endoscopy:  a meta-analysis Di Giulio E, Hassan C, Zullo A, et al. , DLD 2009 ASGE guidelines Sens. Spec. PPV NPV Relevant finding 85% 28% 49% 70% Cancer 97% 22% 2% 99.8%
ASGE GUIDELINES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
ASMaD Onlus www.santeugenioroma.org
[object Object]
RESULTS Table 4.  Multivariate analysis for the detection of relevant finding Clinical variable Relevant finding  OR (95% CI) Bleeding 3.51 (2.9  –  4.2) Relevant finding at previous EGD 2.76 (2.5  –  3.1) Appropriateness 2.7 (2.4  –  3) Male sex 1.77 (1.6  –  1.9) Age  > 45 1.55 (1.4  –  1.7) Alarm symptoms 1.39 (1.2  –  1.6) Weight loss 1.32 (1  –  1.6) Reflux 1.16 (1.05  –  1.3) PPI therapy 1.03 (0.93  –  1.1)
RESULTS Table 5.  Estimates of accuracy of the different strategies in selecting EGD referrals for the detection of relevant findings  b) Strategy Rate of EGDs indicated Sens. Spec. PPV NPV AUC ASGE guidelines 80% 88% 27% 51% 72% 0.55 Age  > 45/alarm  features 78% 82% 26% 49% 63% 0.52
RESULTS Figure 1.  Receiver operating curve (ROC) for multivariate and ANN models for relevant findings.  b)
RESULTS Table 4.  Multivariate analysis for the detection of malignancy b) Clinical variable New malignancy  OR (95% CI) Weight loss 15.2 (9.3 – 24.8) Dysphagia 9.3 (5.7 – 15.6) Alarm features 8 .78 (5.2 – 14.8) Age 8.2 (2.8 – 24) Age  > 45 years 8 (2.6 – 23.8) Age  > 45 years  or  alarm features 7.63 (2.3 – 24.7) Vomiting 5.64 (3.2 – 10.1) No previous EGD 7.5 (2 – 28) Anaemia 3.66 (2.2 – 6.1) Bleeding 1.91 (0.5 – 6.4) Family history for cancer 1.77 (0.5 – 6.7) Male sex 1.63 (1 – 2.6) Specialist 1.2 (1 – 2) NSAIDs/anti-COX2/aspirin 1 (0.5 – 2.2)
RESULTS Table 5.  Estimates of accuracy of the different strategies in selecting EGD referrals for the detection of cancer b) Strategy Sens. Spec. PPV NPV NNT AUC ASGE guidelines 98% 20% 2% 99.8% 50 0.59 Age > 45/alarm features 97% 22% 2% 99.8% 50 0.59
RESULTS Figure 1.  Receiver operating curve (ROC) for multivariate and ANN models for new cases of malignancy .  b)
CONCLUSIONS b) ,[object Object],[object Object],[object Object]
Buri L, Hassan C,Bersani G , Anti M, Bianco MA, Cipolletta L, Di Giulio E, Di Matteo G, Familiari  L, Ficano L, Loriga P, Morini S, Pietropaolo V,  Zambelli A, Grossi E, Intraligi M, and the SIED Appropriateness Working Group.* Appropriateness guidelines and predictive rules to select patients for upper endoscopy:  a nationwide, multicenter study on behalf of SIED
CANCER RELEVANT FINDINGS NO CANCER 4% 96%
METHODS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
METHODS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
METHODS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
RESULTS b) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CONCLUSIONS ,[object Object],[object Object],[object Object]
“ In conclusion, our study showed that a simple rule based on age and alarm features may be as accurate as the more complex ASGE guidelines in predicting endoscopic outcome in an unselected EGD population.  The implementation of such predictive rule would immediately result in the exclusion of more than 20% of the patients from the EGD waiting list, with only a marginal loss of clinical information. Linear and ANN models may be useful to prioritize patients at higher risk of malignancy.”
b)
b)

More Related Content

What's hot

Guideline Development Discussion
Guideline Development DiscussionGuideline Development Discussion
Guideline Development Discussionaccurayexchange
 
Trauma and urologic reconstruction network of surgeons - MMC and BNCX
Trauma and urologic reconstruction network of surgeons - MMC and BNCXTrauma and urologic reconstruction network of surgeons - MMC and BNCX
Trauma and urologic reconstruction network of surgeons - MMC and BNCXjeremybmyers
 
NY Prostate Cancer Conference - H. Van Poppel - Session 8: Do I need a nomogr...
NY Prostate Cancer Conference - H. Van Poppel - Session 8: Do I need a nomogr...NY Prostate Cancer Conference - H. Van Poppel - Session 8: Do I need a nomogr...
NY Prostate Cancer Conference - H. Van Poppel - Session 8: Do I need a nomogr...European School of Oncology
 
MCO 2011 - Slide 21 - P. Rougier - Adjuvant treatment (stage 2 and 3)
MCO 2011 - Slide 21 - P. Rougier - Adjuvant treatment (stage 2 and 3)MCO 2011 - Slide 21 - P. Rougier - Adjuvant treatment (stage 2 and 3)
MCO 2011 - Slide 21 - P. Rougier - Adjuvant treatment (stage 2 and 3)European School of Oncology
 
Radical Salvage Prostatectomy with Pelvic Lymphadenectomy Extended Post Prima...
Radical Salvage Prostatectomy with Pelvic Lymphadenectomy Extended Post Prima...Radical Salvage Prostatectomy with Pelvic Lymphadenectomy Extended Post Prima...
Radical Salvage Prostatectomy with Pelvic Lymphadenectomy Extended Post Prima...CrimsonPublishersUrologyJournal
 
Stereotactic Ablative RT in HCC
Stereotactic Ablative RT in HCCStereotactic Ablative RT in HCC
Stereotactic Ablative RT in HCCaccurayexchange
 
ECCLU 2011 - K. Fizazi - Prostate cancer: Locally advanced disease and patien...
ECCLU 2011 - K. Fizazi - Prostate cancer: Locally advanced disease and patien...ECCLU 2011 - K. Fizazi - Prostate cancer: Locally advanced disease and patien...
ECCLU 2011 - K. Fizazi - Prostate cancer: Locally advanced disease and patien...European School of Oncology
 
Radiological evaluation aasld 2011
Radiological evaluation aasld 2011Radiological evaluation aasld 2011
Radiological evaluation aasld 2011mbouattour
 
MCO 2011 - Slide 8 - E. Senkus-Konefka - Treatment of metastatic disease and ...
MCO 2011 - Slide 8 - E. Senkus-Konefka - Treatment of metastatic disease and ...MCO 2011 - Slide 8 - E. Senkus-Konefka - Treatment of metastatic disease and ...
MCO 2011 - Slide 8 - E. Senkus-Konefka - Treatment of metastatic disease and ...European School of Oncology
 
NY Prostate Cancer Conference - V.E. Reuter - Session 2: Upgrading/downgradin...
NY Prostate Cancer Conference - V.E. Reuter - Session 2: Upgrading/downgradin...NY Prostate Cancer Conference - V.E. Reuter - Session 2: Upgrading/downgradin...
NY Prostate Cancer Conference - V.E. Reuter - Session 2: Upgrading/downgradin...European School of Oncology
 
NY Prostate Cancer Conference - L. Klotz - Session 3: Active surveillance: PS...
NY Prostate Cancer Conference - L. Klotz - Session 3: Active surveillance: PS...NY Prostate Cancer Conference - L. Klotz - Session 3: Active surveillance: PS...
NY Prostate Cancer Conference - L. Klotz - Session 3: Active surveillance: PS...European School of Oncology
 
Radiosurgery (CyberKnife) in Liver Tumours: Indian Experience
Radiosurgery (CyberKnife) in Liver Tumours: Indian ExperienceRadiosurgery (CyberKnife) in Liver Tumours: Indian Experience
Radiosurgery (CyberKnife) in Liver Tumours: Indian Experienceduttaradio
 
RECTUM CANCER MANAGEMENT
RECTUM CANCER MANAGEMENTRECTUM CANCER MANAGEMENT
RECTUM CANCER MANAGEMENTKanhu Charan
 
John Tidy - Adjunctive colposcopic technologies
John Tidy - Adjunctive colposcopic technologiesJohn Tidy - Adjunctive colposcopic technologies
John Tidy - Adjunctive colposcopic technologiestriumphbenelux
 

What's hot (20)

SENTINA Trial
SENTINA TrialSENTINA Trial
SENTINA Trial
 
040044947
040044947040044947
040044947
 
Evaluation of Alvarado Score
Evaluation of Alvarado ScoreEvaluation of Alvarado Score
Evaluation of Alvarado Score
 
Spectrum of Cervical Lesions by Papanicolaou (Pap) Smear Screening in Remote ...
Spectrum of Cervical Lesions by Papanicolaou (Pap) Smear Screening in Remote ...Spectrum of Cervical Lesions by Papanicolaou (Pap) Smear Screening in Remote ...
Spectrum of Cervical Lesions by Papanicolaou (Pap) Smear Screening in Remote ...
 
Guideline Development Discussion
Guideline Development DiscussionGuideline Development Discussion
Guideline Development Discussion
 
Trauma and urologic reconstruction network of surgeons - MMC and BNCX
Trauma and urologic reconstruction network of surgeons - MMC and BNCXTrauma and urologic reconstruction network of surgeons - MMC and BNCX
Trauma and urologic reconstruction network of surgeons - MMC and BNCX
 
NY Prostate Cancer Conference - H. Van Poppel - Session 8: Do I need a nomogr...
NY Prostate Cancer Conference - H. Van Poppel - Session 8: Do I need a nomogr...NY Prostate Cancer Conference - H. Van Poppel - Session 8: Do I need a nomogr...
NY Prostate Cancer Conference - H. Van Poppel - Session 8: Do I need a nomogr...
 
MCO 2011 - Slide 21 - P. Rougier - Adjuvant treatment (stage 2 and 3)
MCO 2011 - Slide 21 - P. Rougier - Adjuvant treatment (stage 2 and 3)MCO 2011 - Slide 21 - P. Rougier - Adjuvant treatment (stage 2 and 3)
MCO 2011 - Slide 21 - P. Rougier - Adjuvant treatment (stage 2 and 3)
 
Radical Salvage Prostatectomy with Pelvic Lymphadenectomy Extended Post Prima...
Radical Salvage Prostatectomy with Pelvic Lymphadenectomy Extended Post Prima...Radical Salvage Prostatectomy with Pelvic Lymphadenectomy Extended Post Prima...
Radical Salvage Prostatectomy with Pelvic Lymphadenectomy Extended Post Prima...
 
NET - Kennecke
NET - KenneckeNET - Kennecke
NET - Kennecke
 
Stereotactic Ablative RT in HCC
Stereotactic Ablative RT in HCCStereotactic Ablative RT in HCC
Stereotactic Ablative RT in HCC
 
Landmark trials in Ovarian Cancer
Landmark trials in Ovarian CancerLandmark trials in Ovarian Cancer
Landmark trials in Ovarian Cancer
 
ECCLU 2011 - K. Fizazi - Prostate cancer: Locally advanced disease and patien...
ECCLU 2011 - K. Fizazi - Prostate cancer: Locally advanced disease and patien...ECCLU 2011 - K. Fizazi - Prostate cancer: Locally advanced disease and patien...
ECCLU 2011 - K. Fizazi - Prostate cancer: Locally advanced disease and patien...
 
Radiological evaluation aasld 2011
Radiological evaluation aasld 2011Radiological evaluation aasld 2011
Radiological evaluation aasld 2011
 
MCO 2011 - Slide 8 - E. Senkus-Konefka - Treatment of metastatic disease and ...
MCO 2011 - Slide 8 - E. Senkus-Konefka - Treatment of metastatic disease and ...MCO 2011 - Slide 8 - E. Senkus-Konefka - Treatment of metastatic disease and ...
MCO 2011 - Slide 8 - E. Senkus-Konefka - Treatment of metastatic disease and ...
 
NY Prostate Cancer Conference - V.E. Reuter - Session 2: Upgrading/downgradin...
NY Prostate Cancer Conference - V.E. Reuter - Session 2: Upgrading/downgradin...NY Prostate Cancer Conference - V.E. Reuter - Session 2: Upgrading/downgradin...
NY Prostate Cancer Conference - V.E. Reuter - Session 2: Upgrading/downgradin...
 
NY Prostate Cancer Conference - L. Klotz - Session 3: Active surveillance: PS...
NY Prostate Cancer Conference - L. Klotz - Session 3: Active surveillance: PS...NY Prostate Cancer Conference - L. Klotz - Session 3: Active surveillance: PS...
NY Prostate Cancer Conference - L. Klotz - Session 3: Active surveillance: PS...
 
Radiosurgery (CyberKnife) in Liver Tumours: Indian Experience
Radiosurgery (CyberKnife) in Liver Tumours: Indian ExperienceRadiosurgery (CyberKnife) in Liver Tumours: Indian Experience
Radiosurgery (CyberKnife) in Liver Tumours: Indian Experience
 
RECTUM CANCER MANAGEMENT
RECTUM CANCER MANAGEMENTRECTUM CANCER MANAGEMENT
RECTUM CANCER MANAGEMENT
 
John Tidy - Adjunctive colposcopic technologies
John Tidy - Adjunctive colposcopic technologiesJohn Tidy - Adjunctive colposcopic technologies
John Tidy - Adjunctive colposcopic technologies
 

Viewers also liked

Mens urological health cme bph-luts- final- nov 13 2013
Mens urological health cme   bph-luts- final- nov 13 2013Mens urological health cme   bph-luts- final- nov 13 2013
Mens urological health cme bph-luts- final- nov 13 2013Ihsaan Peer
 
Benign Prostatic Hyperplasia & Incontinence New
Benign Prostatic Hyperplasia & Incontinence NewBenign Prostatic Hyperplasia & Incontinence New
Benign Prostatic Hyperplasia & Incontinence NewAnil Haripriya
 
Medical management of bph
Medical management of bphMedical management of bph
Medical management of bphOmar Akhtar
 
Medical management of bph
Medical management of bphMedical management of bph
Medical management of bphbbthapa
 
Benign Prostatic Hyperplasia (BPH and LUTS)
Benign Prostatic Hyperplasia (BPH and LUTS)Benign Prostatic Hyperplasia (BPH and LUTS)
Benign Prostatic Hyperplasia (BPH and LUTS)Abdullah Mohammad
 
Benigh prostatic hyperplasia
Benigh prostatic hyperplasiaBenigh prostatic hyperplasia
Benigh prostatic hyperplasiaVivian Barrera
 

Viewers also liked (8)

Mens urological health cme bph-luts- final- nov 13 2013
Mens urological health cme   bph-luts- final- nov 13 2013Mens urological health cme   bph-luts- final- nov 13 2013
Mens urological health cme bph-luts- final- nov 13 2013
 
Principles of management,bph
Principles of management,bphPrinciples of management,bph
Principles of management,bph
 
Benign Prostatic Hyperplasia & Incontinence New
Benign Prostatic Hyperplasia & Incontinence NewBenign Prostatic Hyperplasia & Incontinence New
Benign Prostatic Hyperplasia & Incontinence New
 
Medical management of bph
Medical management of bphMedical management of bph
Medical management of bph
 
Medical management of bph
Medical management of bphMedical management of bph
Medical management of bph
 
Benign Prostatic Hyperplasia (BPH and LUTS)
Benign Prostatic Hyperplasia (BPH and LUTS)Benign Prostatic Hyperplasia (BPH and LUTS)
Benign Prostatic Hyperplasia (BPH and LUTS)
 
Benigh prostatic hyperplasia
Benigh prostatic hyperplasiaBenigh prostatic hyperplasia
Benigh prostatic hyperplasia
 
Benign Prostatic Hyperplasia
Benign Prostatic HyperplasiaBenign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
 

Similar to Appropriateness of Upper Endoscopy: A Nationwide Study

12 Quimioterapia, 1ª - 2ª línea y mantenimiento. Cáncer de Pulmón
12 Quimioterapia, 1ª - 2ª línea y mantenimiento. Cáncer de Pulmón12 Quimioterapia, 1ª - 2ª línea y mantenimiento. Cáncer de Pulmón
12 Quimioterapia, 1ª - 2ª línea y mantenimiento. Cáncer de PulmónEffyciens Marketing Online SL.
 
CCO_Pancreatic_Cancer_Advances_Downloadable_4 (2).pptx
CCO_Pancreatic_Cancer_Advances_Downloadable_4 (2).pptxCCO_Pancreatic_Cancer_Advances_Downloadable_4 (2).pptx
CCO_Pancreatic_Cancer_Advances_Downloadable_4 (2).pptxANNELIESEKARINALVARA1
 
Clinical Impact of New NAFLD/NASH Data From San Francisco 2018
Clinical Impact of New NAFLD/NASH Data From San Francisco 2018Clinical Impact of New NAFLD/NASH Data From San Francisco 2018
Clinical Impact of New NAFLD/NASH Data From San Francisco 2018hivlifeinfo
 
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...European School of Oncology
 
Rare Solid Cancers: An Introduction - Slide 7 - A. Berruti - Adrenal cancer
Rare Solid Cancers: An Introduction - Slide 7 - A. Berruti - Adrenal cancerRare Solid Cancers: An Introduction - Slide 7 - A. Berruti - Adrenal cancer
Rare Solid Cancers: An Introduction - Slide 7 - A. Berruti - Adrenal cancerEuropean School of Oncology
 
Gallbladder CA.pptx
Gallbladder CA.pptxGallbladder CA.pptx
Gallbladder CA.pptxTiwariKripa
 
Endoscopy in Gastrointestinal Oncology - Slide 10 - M. Barthet - Management o...
Endoscopy in Gastrointestinal Oncology - Slide 10 - M. Barthet - Management o...Endoscopy in Gastrointestinal Oncology - Slide 10 - M. Barthet - Management o...
Endoscopy in Gastrointestinal Oncology - Slide 10 - M. Barthet - Management o...European School of Oncology
 
Crespi, there are conflicting data about efficacy of colonoscopy
Crespi, there are conflicting data about efficacy of colonoscopy Crespi, there are conflicting data about efficacy of colonoscopy
Crespi, there are conflicting data about efficacy of colonoscopy Gianfranco Tammaro
 
L'esofago di Barrett - Gastrolearning®
L'esofago di Barrett -  Gastrolearning®L'esofago di Barrett -  Gastrolearning®
L'esofago di Barrett - Gastrolearning®Gastrolearning
 
CT coronary angiography in ED chest pain patients
CT coronary angiography in ED chest pain patientsCT coronary angiography in ED chest pain patients
CT coronary angiography in ED chest pain patientskellyam18
 
Integrating icosapent ethyl in clinical practice: which patients will benefits?
Integrating icosapent ethyl in clinical practice: which patients will benefits?Integrating icosapent ethyl in clinical practice: which patients will benefits?
Integrating icosapent ethyl in clinical practice: which patients will benefits?Sociedad Española de Cardiología
 

Similar to Appropriateness of Upper Endoscopy: A Nationwide Study (20)

1 Crespi Screening Rettocolon
1 Crespi Screening Rettocolon1 Crespi Screening Rettocolon
1 Crespi Screening Rettocolon
 
Update from CROI 2018: Focus on TB and Other Opportunistic Infections
Update from CROI 2018: Focus on TB and Other Opportunistic InfectionsUpdate from CROI 2018: Focus on TB and Other Opportunistic Infections
Update from CROI 2018: Focus on TB and Other Opportunistic Infections
 
12 Quimioterapia, 1ª - 2ª línea y mantenimiento. Cáncer de Pulmón
12 Quimioterapia, 1ª - 2ª línea y mantenimiento. Cáncer de Pulmón12 Quimioterapia, 1ª - 2ª línea y mantenimiento. Cáncer de Pulmón
12 Quimioterapia, 1ª - 2ª línea y mantenimiento. Cáncer de Pulmón
 
CCO_Pancreatic_Cancer_Advances_Downloadable_4 (2).pptx
CCO_Pancreatic_Cancer_Advances_Downloadable_4 (2).pptxCCO_Pancreatic_Cancer_Advances_Downloadable_4 (2).pptx
CCO_Pancreatic_Cancer_Advances_Downloadable_4 (2).pptx
 
Clinical Impact of New NAFLD/NASH Data From San Francisco 2018
Clinical Impact of New NAFLD/NASH Data From San Francisco 2018Clinical Impact of New NAFLD/NASH Data From San Francisco 2018
Clinical Impact of New NAFLD/NASH Data From San Francisco 2018
 
Appendix by drdamodhar.m.v
Appendix by drdamodhar.m.vAppendix by drdamodhar.m.v
Appendix by drdamodhar.m.v
 
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...
 
19 im resident future of rectal cancer
19 im resident future of rectal cancer19 im resident future of rectal cancer
19 im resident future of rectal cancer
 
Rare Solid Cancers: An Introduction - Slide 7 - A. Berruti - Adrenal cancer
Rare Solid Cancers: An Introduction - Slide 7 - A. Berruti - Adrenal cancerRare Solid Cancers: An Introduction - Slide 7 - A. Berruti - Adrenal cancer
Rare Solid Cancers: An Introduction - Slide 7 - A. Berruti - Adrenal cancer
 
Gallbladder CA.pptx
Gallbladder CA.pptxGallbladder CA.pptx
Gallbladder CA.pptx
 
Endoscopy in Gastrointestinal Oncology - Slide 10 - M. Barthet - Management o...
Endoscopy in Gastrointestinal Oncology - Slide 10 - M. Barthet - Management o...Endoscopy in Gastrointestinal Oncology - Slide 10 - M. Barthet - Management o...
Endoscopy in Gastrointestinal Oncology - Slide 10 - M. Barthet - Management o...
 
Crespi, there are conflicting data about efficacy of colonoscopy
Crespi, there are conflicting data about efficacy of colonoscopy Crespi, there are conflicting data about efficacy of colonoscopy
Crespi, there are conflicting data about efficacy of colonoscopy
 
L'esofago di Barrett - Gastrolearning®
L'esofago di Barrett -  Gastrolearning®L'esofago di Barrett -  Gastrolearning®
L'esofago di Barrett - Gastrolearning®
 
CT coronary angiography in ED chest pain patients
CT coronary angiography in ED chest pain patientsCT coronary angiography in ED chest pain patients
CT coronary angiography in ED chest pain patients
 
MCC 2011 - Slide 7
MCC 2011 - Slide 7MCC 2011 - Slide 7
MCC 2011 - Slide 7
 
Sciahbasi A - AIMRADIAL 2013 - Radiation exposure
Sciahbasi A - AIMRADIAL 2013 - Radiation exposureSciahbasi A - AIMRADIAL 2013 - Radiation exposure
Sciahbasi A - AIMRADIAL 2013 - Radiation exposure
 
Integrating icosapent ethyl in clinical practice: which patients will benefits?
Integrating icosapent ethyl in clinical practice: which patients will benefits?Integrating icosapent ethyl in clinical practice: which patients will benefits?
Integrating icosapent ethyl in clinical practice: which patients will benefits?
 
MCC 2011 - Slide 14
MCC 2011 - Slide 14MCC 2011 - Slide 14
MCC 2011 - Slide 14
 
HCC20121001
HCC20121001 HCC20121001
HCC20121001
 
4 dr mario sideri m k
4  dr mario sideri  m k4  dr mario sideri  m k
4 dr mario sideri m k
 

More from Gianfranco Tammaro

Il Trattamento Insulinico del Diabete tipo 1
Il Trattamento Insulinico del Diabete tipo 1Il Trattamento Insulinico del Diabete tipo 1
Il Trattamento Insulinico del Diabete tipo 1Gianfranco Tammaro
 
SANDRI G. La Nutrizione Clinica al S.Eugenio. ASMaD 2017
SANDRI G. La Nutrizione Clinica al S.Eugenio. ASMaD 2017SANDRI G. La Nutrizione Clinica al S.Eugenio. ASMaD 2017
SANDRI G. La Nutrizione Clinica al S.Eugenio. ASMaD 2017Gianfranco Tammaro
 
GASBARRINI A. Nutrizione Clinica e Gastroenterologia. ASMaD 2017
GASBARRINI A. Nutrizione Clinica e Gastroenterologia. ASMaD 2017GASBARRINI A. Nutrizione Clinica e Gastroenterologia. ASMaD 2017
GASBARRINI A. Nutrizione Clinica e Gastroenterologia. ASMaD 2017Gianfranco Tammaro
 
PALLAGROSI R. Gli Alimenti a fini medici speciali: nuova definizione e normat...
PALLAGROSI R. Gli Alimenti a fini medici speciali: nuova definizione e normat...PALLAGROSI R. Gli Alimenti a fini medici speciali: nuova definizione e normat...
PALLAGROSI R. Gli Alimenti a fini medici speciali: nuova definizione e normat...Gianfranco Tammaro
 
DE SANTIS D. Il Supporto Nutrizionale in Ospedale: ieri, oggi, domani. ASMaD ...
DE SANTIS D. Il Supporto Nutrizionale in Ospedale: ieri, oggi, domani. ASMaD ...DE SANTIS D. Il Supporto Nutrizionale in Ospedale: ieri, oggi, domani. ASMaD ...
DE SANTIS D. Il Supporto Nutrizionale in Ospedale: ieri, oggi, domani. ASMaD ...Gianfranco Tammaro
 
Giorgetti G.M. Il Supporto Nutrizionale in Ospedale: ieri, oggi, domani. ASMa...
Giorgetti G.M. Il Supporto Nutrizionale in Ospedale: ieri, oggi, domani. ASMa...Giorgetti G.M. Il Supporto Nutrizionale in Ospedale: ieri, oggi, domani. ASMa...
Giorgetti G.M. Il Supporto Nutrizionale in Ospedale: ieri, oggi, domani. ASMa...Gianfranco Tammaro
 
Franceschi F. Il Ruolo del Gastroenterologo nel DEA. ASMaD 2016
Franceschi F. Il Ruolo del Gastroenterologo nel DEA. ASMaD 2016Franceschi F. Il Ruolo del Gastroenterologo nel DEA. ASMaD 2016
Franceschi F. Il Ruolo del Gastroenterologo nel DEA. ASMaD 2016Gianfranco Tammaro
 
Pace F. La Malattia da Reflusso Gastroesofageo. ASMaD 2016
Pace F. La Malattia da Reflusso Gastroesofageo. ASMaD 2016Pace F. La Malattia da Reflusso Gastroesofageo. ASMaD 2016
Pace F. La Malattia da Reflusso Gastroesofageo. ASMaD 2016Gianfranco Tammaro
 
Ianiro G. La Malattia Celiaca. ASMaD 2016
Ianiro G. La Malattia Celiaca. ASMaD 2016Ianiro G. La Malattia Celiaca. ASMaD 2016
Ianiro G. La Malattia Celiaca. ASMaD 2016Gianfranco Tammaro
 
Corazziari E. La Stipsi. ASMaD 2016
Corazziari E. La Stipsi. ASMaD 2016Corazziari E. La Stipsi. ASMaD 2016
Corazziari E. La Stipsi. ASMaD 2016Gianfranco Tammaro
 
Tringali A. La CPRE. ASMaD 2016
Tringali A. La CPRE. ASMaD 2016Tringali A. La CPRE. ASMaD 2016
Tringali A. La CPRE. ASMaD 2016Gianfranco Tammaro
 
Gasbarrini A. Microbiota, Antibiotici e Probiotici in Gastroenterologia. ASMa...
Gasbarrini A. Microbiota, Antibiotici e Probiotici in Gastroenterologia. ASMa...Gasbarrini A. Microbiota, Antibiotici e Probiotici in Gastroenterologia. ASMa...
Gasbarrini A. Microbiota, Antibiotici e Probiotici in Gastroenterologia. ASMa...Gianfranco Tammaro
 
Attili F. L'Ecoendoscopia. ASMaD 2016
Attili F. L'Ecoendoscopia. ASMaD 2016Attili F. L'Ecoendoscopia. ASMaD 2016
Attili F. L'Ecoendoscopia. ASMaD 2016Gianfranco Tammaro
 
Petruzziello L. La Colonscopia di qualità e le Procedure operative. ASMaD 2016
Petruzziello L. La Colonscopia di qualità e le Procedure operative. ASMaD 2016Petruzziello L. La Colonscopia di qualità e le Procedure operative. ASMaD 2016
Petruzziello L. La Colonscopia di qualità e le Procedure operative. ASMaD 2016Gianfranco Tammaro
 
Bellini M. La Manometria del Tratto Inferiore. ASMaD 2016
Bellini M. La Manometria del Tratto Inferiore. ASMaD 2016Bellini M. La Manometria del Tratto Inferiore. ASMaD 2016
Bellini M. La Manometria del Tratto Inferiore. ASMaD 2016Gianfranco Tammaro
 
De Bortoli N. La Manometria del Tratto Superiore. ASMaD 2016
De Bortoli N. La Manometria del Tratto Superiore. ASMaD 2016De Bortoli N. La Manometria del Tratto Superiore. ASMaD 2016
De Bortoli N. La Manometria del Tratto Superiore. ASMaD 2016Gianfranco Tammaro
 
Frazzoni M. La PH-Impedenzometria. ASMaD 2016
Frazzoni M. La PH-Impedenzometria. ASMaD 2016Frazzoni M. La PH-Impedenzometria. ASMaD 2016
Frazzoni M. La PH-Impedenzometria. ASMaD 2016Gianfranco Tammaro
 
Cerro P. La Radiologia Convenzionale del Tubo Digerente - Studio della deglut...
Cerro P. La Radiologia Convenzionale del Tubo Digerente - Studio della deglut...Cerro P. La Radiologia Convenzionale del Tubo Digerente - Studio della deglut...
Cerro P. La Radiologia Convenzionale del Tubo Digerente - Studio della deglut...Gianfranco Tammaro
 
Scaldaferri F. Breath Test cosa c'è di nuovo. ASMaD 2016
Scaldaferri F. Breath Test cosa c'è di nuovo. ASMaD 2016Scaldaferri F. Breath Test cosa c'è di nuovo. ASMaD 2016
Scaldaferri F. Breath Test cosa c'è di nuovo. ASMaD 2016Gianfranco Tammaro
 
Caturelli E. L'Ecografia Operativa. ASMaD 2016
Caturelli E. L'Ecografia Operativa. ASMaD 2016Caturelli E. L'Ecografia Operativa. ASMaD 2016
Caturelli E. L'Ecografia Operativa. ASMaD 2016Gianfranco Tammaro
 

More from Gianfranco Tammaro (20)

Il Trattamento Insulinico del Diabete tipo 1
Il Trattamento Insulinico del Diabete tipo 1Il Trattamento Insulinico del Diabete tipo 1
Il Trattamento Insulinico del Diabete tipo 1
 
SANDRI G. La Nutrizione Clinica al S.Eugenio. ASMaD 2017
SANDRI G. La Nutrizione Clinica al S.Eugenio. ASMaD 2017SANDRI G. La Nutrizione Clinica al S.Eugenio. ASMaD 2017
SANDRI G. La Nutrizione Clinica al S.Eugenio. ASMaD 2017
 
GASBARRINI A. Nutrizione Clinica e Gastroenterologia. ASMaD 2017
GASBARRINI A. Nutrizione Clinica e Gastroenterologia. ASMaD 2017GASBARRINI A. Nutrizione Clinica e Gastroenterologia. ASMaD 2017
GASBARRINI A. Nutrizione Clinica e Gastroenterologia. ASMaD 2017
 
PALLAGROSI R. Gli Alimenti a fini medici speciali: nuova definizione e normat...
PALLAGROSI R. Gli Alimenti a fini medici speciali: nuova definizione e normat...PALLAGROSI R. Gli Alimenti a fini medici speciali: nuova definizione e normat...
PALLAGROSI R. Gli Alimenti a fini medici speciali: nuova definizione e normat...
 
DE SANTIS D. Il Supporto Nutrizionale in Ospedale: ieri, oggi, domani. ASMaD ...
DE SANTIS D. Il Supporto Nutrizionale in Ospedale: ieri, oggi, domani. ASMaD ...DE SANTIS D. Il Supporto Nutrizionale in Ospedale: ieri, oggi, domani. ASMaD ...
DE SANTIS D. Il Supporto Nutrizionale in Ospedale: ieri, oggi, domani. ASMaD ...
 
Giorgetti G.M. Il Supporto Nutrizionale in Ospedale: ieri, oggi, domani. ASMa...
Giorgetti G.M. Il Supporto Nutrizionale in Ospedale: ieri, oggi, domani. ASMa...Giorgetti G.M. Il Supporto Nutrizionale in Ospedale: ieri, oggi, domani. ASMa...
Giorgetti G.M. Il Supporto Nutrizionale in Ospedale: ieri, oggi, domani. ASMa...
 
Franceschi F. Il Ruolo del Gastroenterologo nel DEA. ASMaD 2016
Franceschi F. Il Ruolo del Gastroenterologo nel DEA. ASMaD 2016Franceschi F. Il Ruolo del Gastroenterologo nel DEA. ASMaD 2016
Franceschi F. Il Ruolo del Gastroenterologo nel DEA. ASMaD 2016
 
Pace F. La Malattia da Reflusso Gastroesofageo. ASMaD 2016
Pace F. La Malattia da Reflusso Gastroesofageo. ASMaD 2016Pace F. La Malattia da Reflusso Gastroesofageo. ASMaD 2016
Pace F. La Malattia da Reflusso Gastroesofageo. ASMaD 2016
 
Ianiro G. La Malattia Celiaca. ASMaD 2016
Ianiro G. La Malattia Celiaca. ASMaD 2016Ianiro G. La Malattia Celiaca. ASMaD 2016
Ianiro G. La Malattia Celiaca. ASMaD 2016
 
Corazziari E. La Stipsi. ASMaD 2016
Corazziari E. La Stipsi. ASMaD 2016Corazziari E. La Stipsi. ASMaD 2016
Corazziari E. La Stipsi. ASMaD 2016
 
Tringali A. La CPRE. ASMaD 2016
Tringali A. La CPRE. ASMaD 2016Tringali A. La CPRE. ASMaD 2016
Tringali A. La CPRE. ASMaD 2016
 
Gasbarrini A. Microbiota, Antibiotici e Probiotici in Gastroenterologia. ASMa...
Gasbarrini A. Microbiota, Antibiotici e Probiotici in Gastroenterologia. ASMa...Gasbarrini A. Microbiota, Antibiotici e Probiotici in Gastroenterologia. ASMa...
Gasbarrini A. Microbiota, Antibiotici e Probiotici in Gastroenterologia. ASMa...
 
Attili F. L'Ecoendoscopia. ASMaD 2016
Attili F. L'Ecoendoscopia. ASMaD 2016Attili F. L'Ecoendoscopia. ASMaD 2016
Attili F. L'Ecoendoscopia. ASMaD 2016
 
Petruzziello L. La Colonscopia di qualità e le Procedure operative. ASMaD 2016
Petruzziello L. La Colonscopia di qualità e le Procedure operative. ASMaD 2016Petruzziello L. La Colonscopia di qualità e le Procedure operative. ASMaD 2016
Petruzziello L. La Colonscopia di qualità e le Procedure operative. ASMaD 2016
 
Bellini M. La Manometria del Tratto Inferiore. ASMaD 2016
Bellini M. La Manometria del Tratto Inferiore. ASMaD 2016Bellini M. La Manometria del Tratto Inferiore. ASMaD 2016
Bellini M. La Manometria del Tratto Inferiore. ASMaD 2016
 
De Bortoli N. La Manometria del Tratto Superiore. ASMaD 2016
De Bortoli N. La Manometria del Tratto Superiore. ASMaD 2016De Bortoli N. La Manometria del Tratto Superiore. ASMaD 2016
De Bortoli N. La Manometria del Tratto Superiore. ASMaD 2016
 
Frazzoni M. La PH-Impedenzometria. ASMaD 2016
Frazzoni M. La PH-Impedenzometria. ASMaD 2016Frazzoni M. La PH-Impedenzometria. ASMaD 2016
Frazzoni M. La PH-Impedenzometria. ASMaD 2016
 
Cerro P. La Radiologia Convenzionale del Tubo Digerente - Studio della deglut...
Cerro P. La Radiologia Convenzionale del Tubo Digerente - Studio della deglut...Cerro P. La Radiologia Convenzionale del Tubo Digerente - Studio della deglut...
Cerro P. La Radiologia Convenzionale del Tubo Digerente - Studio della deglut...
 
Scaldaferri F. Breath Test cosa c'è di nuovo. ASMaD 2016
Scaldaferri F. Breath Test cosa c'è di nuovo. ASMaD 2016Scaldaferri F. Breath Test cosa c'è di nuovo. ASMaD 2016
Scaldaferri F. Breath Test cosa c'è di nuovo. ASMaD 2016
 
Caturelli E. L'Ecografia Operativa. ASMaD 2016
Caturelli E. L'Ecografia Operativa. ASMaD 2016Caturelli E. L'Ecografia Operativa. ASMaD 2016
Caturelli E. L'Ecografia Operativa. ASMaD 2016
 

Recently uploaded

PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATROKanhu Charan
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAAjennyeacort
 
POST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptxPOST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptxvirengeeta
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxDr. Dheeraj Kumar
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Badalona Serveis Assistencials
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxNiranjan Chavan
 
Pharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingPharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingArunagarwal328757
 
Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?bkling
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxSasikiranMarri
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdfDolisha Warbi
 
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptkedirjemalharun
 
Report Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxReport Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxbkling
 
call girls in munirka DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in munirka  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in munirka  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in munirka DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 

Recently uploaded (20)

PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA
 
POST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptxPOST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptx
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptx
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptx
 
Pharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingPharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, Pricing
 
Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptx
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
 
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
Epilepsy
EpilepsyEpilepsy
Epilepsy
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.ppt
 
Report Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxReport Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptx
 
call girls in munirka DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in munirka  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in munirka  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in munirka DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 

Appropriateness of Upper Endoscopy: A Nationwide Study

  • 1. L’ (in) appropriatezza dell’endoscopia superiore C. Hassan
  • 2. ENDOSCOPY PATIENT NON-GI REFERRING PHYSICIAN
  • 3. Medico richiedente N % MMG 3794 60,5 Medico Osped. 2268 36,2 Specialista est. 124 2,0 n.i. 84 1,3 TOTALE 6270 100
  • 4. ENDOSCOPY PATIENT NON-GI REFERRING PHYSICIAN GI GUIDELINES
  • 5.
  • 6. “… on how endoscopy should be performed, by whom, and for what purposes”
  • 7.  
  • 8.  
  • 9.
  • 10.
  • 11.  
  • 12.  
  • 13. 13 856 PATIENTS 22% NOT INDICATED Author N° patients Inappropriateness Rate % Hassan et al. 6270 23 Rossi et al. 1777 16 Chan et al. 1076 12 Froelhich et al. 1681 39 Bersani et al. 2000 10 Al Romaih et al. 80 28 Kaliszan et al. 522 30 Gonvers et al. 450 43
  • 14. Età - Giudizio richiesta A P < 0.05
  • 15. Tip. Esame – Giudizio rich. P < 0.05
  • 18.
  • 19.
  • 20.
  • 21.
  • 22. RESULTS New malignancy 1.6% (132 pts.) -Cancer 128 pts. -Lymphoma 4 pts.
  • 23.
  • 24. 13 856 PATIENTS 45% RELEVANT FINDINGS Author N° patients Relevant findings % Hassan et al. 6270 49 Rossi et al. 1777 45 Chan et al. 1076 38 Froelhich et al. 1681 54 Bersani et al. 2000 51 Al Romaih et al. 80 32 Kaliszan et al. 522 46 Gonvers et al. 450 46
  • 25. 51% 32% NOT INDICATED INDICATED 13 856 PATIENTS 78% 22% RELEVANT FINDINGS RELEVANT FINDINGS
  • 26. Appropriateness of the indication for upper endoscopy: a meta-analysis Di Giulio E, Hassan C, Zullo A, et al. , DLD 2009 ASGE guidelines Sens. Spec. PPV NPV Relevant finding 85% 28% 49% 70%
  • 27. DIAGNOSI RILEVANTI vs APPROPRIATEZZA Endoscopic finding OR [99% CI] Clinically relevant Erosive esophagitis 1.28 [0.35-1.63] Erosive gastritis 1.79 [1.35-2.36] * Esophageal varices 5.65 [2.96-10.8] * Duodenal ulcer 3.38 [1.98-5.76] * Barrett’s esophagus 3.58 [1.59-8.08] * Gastric ulcer 3.41 [1.51-7.71] * Not clinically relevant Nonerosive gastritis 0.78 [0.66-0.9] * Normal 0.40 [0.33-0.49] * Hiatal hernia 0.63 [0.51-0.77] *
  • 28. 2.4% 0.13% NOT INDICATED INDICATED 13 856 PATIENTS 78% 22% CANCER CANCER
  • 29. b) Appropriateness of the indication for upper endoscopy: a meta-analysis Di Giulio E, Hassan C, Zullo A, et al. , DLD 2009 ASGE guidelines Sens. Spec. PPV NPV Relevant finding 85% 28% 49% 70% Cancer 97% 22% 2% 99.8%
  • 30.
  • 32.
  • 33. RESULTS Table 4. Multivariate analysis for the detection of relevant finding Clinical variable Relevant finding OR (95% CI) Bleeding 3.51 (2.9 – 4.2) Relevant finding at previous EGD 2.76 (2.5 – 3.1) Appropriateness 2.7 (2.4 – 3) Male sex 1.77 (1.6 – 1.9) Age > 45 1.55 (1.4 – 1.7) Alarm symptoms 1.39 (1.2 – 1.6) Weight loss 1.32 (1 – 1.6) Reflux 1.16 (1.05 – 1.3) PPI therapy 1.03 (0.93 – 1.1)
  • 34. RESULTS Table 5. Estimates of accuracy of the different strategies in selecting EGD referrals for the detection of relevant findings b) Strategy Rate of EGDs indicated Sens. Spec. PPV NPV AUC ASGE guidelines 80% 88% 27% 51% 72% 0.55 Age > 45/alarm features 78% 82% 26% 49% 63% 0.52
  • 35. RESULTS Figure 1. Receiver operating curve (ROC) for multivariate and ANN models for relevant findings. b)
  • 36. RESULTS Table 4. Multivariate analysis for the detection of malignancy b) Clinical variable New malignancy OR (95% CI) Weight loss 15.2 (9.3 – 24.8) Dysphagia 9.3 (5.7 – 15.6) Alarm features 8 .78 (5.2 – 14.8) Age 8.2 (2.8 – 24) Age > 45 years 8 (2.6 – 23.8) Age > 45 years or alarm features 7.63 (2.3 – 24.7) Vomiting 5.64 (3.2 – 10.1) No previous EGD 7.5 (2 – 28) Anaemia 3.66 (2.2 – 6.1) Bleeding 1.91 (0.5 – 6.4) Family history for cancer 1.77 (0.5 – 6.7) Male sex 1.63 (1 – 2.6) Specialist 1.2 (1 – 2) NSAIDs/anti-COX2/aspirin 1 (0.5 – 2.2)
  • 37. RESULTS Table 5. Estimates of accuracy of the different strategies in selecting EGD referrals for the detection of cancer b) Strategy Sens. Spec. PPV NPV NNT AUC ASGE guidelines 98% 20% 2% 99.8% 50 0.59 Age > 45/alarm features 97% 22% 2% 99.8% 50 0.59
  • 38. RESULTS Figure 1. Receiver operating curve (ROC) for multivariate and ANN models for new cases of malignancy . b)
  • 39.
  • 40. Buri L, Hassan C,Bersani G , Anti M, Bianco MA, Cipolletta L, Di Giulio E, Di Matteo G, Familiari L, Ficano L, Loriga P, Morini S, Pietropaolo V, Zambelli A, Grossi E, Intraligi M, and the SIED Appropriateness Working Group.* Appropriateness guidelines and predictive rules to select patients for upper endoscopy: a nationwide, multicenter study on behalf of SIED
  • 41. CANCER RELEVANT FINDINGS NO CANCER 4% 96%
  • 42.
  • 43.
  • 44.
  • 45.
  • 46.
  • 47. “ In conclusion, our study showed that a simple rule based on age and alarm features may be as accurate as the more complex ASGE guidelines in predicting endoscopic outcome in an unselected EGD population. The implementation of such predictive rule would immediately result in the exclusion of more than 20% of the patients from the EGD waiting list, with only a marginal loss of clinical information. Linear and ANN models may be useful to prioritize patients at higher risk of malignancy.”
  • 48. b)
  • 49. b)